NCT04519151 2023-06-08Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerSheba Medical CenterPhase 2 Recruiting24 enrolled
NCT05422183 2022-06-16Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian CancerZhongda HospitalPhase 2 Unknown20 enrolled